Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.84
- Piotroski Score 2.00
- Grade Buy
- Symbol (CRBU)
- Company Caribou Biosciences, Inc.
- Price $1.99
- Changes Percentage (1.28%)
- Change $0.03
- Day Low $1.91
- Day High $2.04
- Year High $8.33
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/10/2025
- Fiscal Year End N/A
- Average Stock Price Target $3.00
- High Stock Price Target $3.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.38
- Trailing P/E Ratio -1.41
- Forward P/E Ratio -1.41
- P/E Growth -1.41
- Net Income $-102,070,000
Income Statement
Quarterly
Annual
Latest News of CRBU
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock?
A list of top gene editing stocks has been published, including Caribou Biosciences, Inc. CRISPR technology has advanced since the mid-2000s, with over 20 clinical trials underway....
By Yahoo! Finance | 3 weeks ago
